Interplay Between P53 and Non-coding RNAs in the Regulation of EMT in Breast Cancer

Overview

Journal Cell Death Dis

Specialties Cell Biology
General Medicine

Date 2021 Jan 8

PMID 33414456

Citations 34

Authors

Sergey Parfenyev

Aastha Singh

Olga Fedorova

Alexandra Daks

Ritu Kulshreshtha

Niskolai A Barlev

Affiliations

Soon will be listed here.

Abstract

The epithelial-mesenchymal transition (EMT) plays a pivotal role in the differentiation of vertebrates and is critically important in tumorigenesis. Using this evolutionarily conserved mechanism, cancer cells become drug-resistant and acquire the ability to escape the cytotoxic effect of anti-cancer drugs. In addition, these cells gain invasive features and increased mobility thereby promoting metastases. In this respect, the process of EMT is critical for dissemination of solid tumors including breast cancer. It has been shown that miRNAs are instrumental for the regulation of EMT, where they play both positive and negative roles often as a part of a feed-back loop. Recent studies have highlighted a novel association of p53 and EMT where the mutation status of p53 is critically important for the outcome of this process. Interestingly, p53 has been shown to mediate its effects via the miRNA-dependent mechanism that targets master-regulators of EMT, such as Zeb1/2, Snail, Slug, and Twist1. This regulation often involves interactions of miRNAs with lncRNAs. In this review, we present a detailed overview of miRNA/lncRNA-dependent mechanisms that control interplay between p53 and master-regulators of EMT and their importance for breast cancer.

Citing Articles

Advanced Insights into Competitive Endogenous RNAs (ceRNAs) Regulated Pathogenic Mechanisms in Metastatic Triple-Negative Breast Cancer (mTNBC).

Qattan A, Al-Tweigeri T, Suleman K, Alkhayal W, Tulbah A Cancers (Basel). 2024; 16(17).

PMID: 39272915 PMC: 11394539. DOI: 10.3390/cancers16173057.

Inhibition of Mir-21-5p Affects the Expression of LNCRNA X-Inactive Specific Transcript and Induces Apoptosis in MCF-7 Breast Cancer Cells.

Nejaddehghan S, Zargar S, Oloomi M, Baesi K, Kouhsar M Iran J Public Health. 2024; 53(3):714-725.

PMID: 38919297 PMC: 11194654. DOI: 10.18502/ijph.v53i3.15154.

Lysine-specific methyltransferase Set7/9 in stemness, differentiation, and development.

Daks A, Parfenyev S, Shuvalov O, Fedorova O, Nazarov A, Melino G Biol Direct. 2024; 19(1):41.

PMID: 38812048 PMC: 11137904. DOI: 10.1186/s13062-024-00484-z.

KDM7A-DT induces genotoxic stress, tumorigenesis, and progression of p53 missense mutation-associated invasive breast cancer.

Giannakakis A, Tsifintaris M, Gouzouasis V, Ow G, Aau M, Papp C Front Oncol. 2024; 14:1227151.

PMID: 38756663 PMC: 11097164. DOI: 10.3389/fonc.2024.1227151.

EVA1A reverses lenvatinib resistance in hepatocellular carcinoma through regulating PI3K/AKT/p53 signaling axis.

Liu X, Gao X, Yang Y, Yang D, Guo Q, Li L Apoptosis. 2024; 29(7-8):1161-1184.

PMID: 38743191 DOI: 10.1007/s10495-024-01967-0.

References

Redig A, McAllister S . Breast cancer as a systemic disease: a view of metastasis. J Intern Med. 2013; 274(2):113-26. PMC: 3711134. DOI: 10.1111/joim.12084. View

Nassar F, Nasr R, Talhouk R . MicroRNAs as biomarkers for early breast cancer diagnosis, prognosis and therapy prediction. Pharmacol Ther. 2016; 172:34-49. DOI: 10.1016/j.pharmthera.2016.11.012. View

Frisch S, Schaller M, Cieply B . Mechanisms that link the oncogenic epithelial-mesenchymal transition to suppression of anoikis. J Cell Sci. 2013; 126(Pt 1):21-9. PMC: 3603508. DOI: 10.1242/jcs.120907. View

Kurrey N, Jalgaonkar S, Joglekar A, Ghanate A, Chaskar P, Doiphode R . Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells. 2009; 27(9):2059-68. DOI: 10.1002/stem.154. View

Tiwari V . Burn wound: How it differs from other wounds?. Indian J Plast Surg. 2012; 45(2):364-73. PMC: 3495387. DOI: 10.4103/0970-0358.101319. View

Chaffer C, Marjanovic N, Lee T, Bell G, Kleer C, Reinhardt F . Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell. 2013; 154(1):61-74. PMC: 4015106. DOI: 10.1016/j.cell.2013.06.005. View

Eger A, Aigner K, Sonderegger S, Dampier B, Oehler S, Schreiber M . DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene. 2005; 24(14):2375-85. DOI: 10.1038/sj.onc.1208429. View

Comijn J, Berx G, Vermassen P, Verschueren K, van Grunsven L, Bruyneel E . The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell. 2001; 7(6):1267-78. DOI: 10.1016/s1097-2765(01)00260-x. View

10.

Hajra K, Fearon E . The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res. 2002; 62(6):1613-8. View

11.

Yang J, Mani S, Liu Donaher J, Ramaswamy S, Itzykson R, Come C . Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004; 117(7):927-39. DOI: 10.1016/j.cell.2004.06.006. View

12.

Shi J, Wang Y, Zeng L, Wu Y, Deng J, Zhang Q . Disrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer. Cancer Cell. 2014; 25(2):210-25. PMC: 4004960. DOI: 10.1016/j.ccr.2014.01.028. View

13.

Li Y, Wu Y, Abbatiello T, Wu W, Kim J, Sarkissyan M . Slug contributes to cancer progression by direct regulation of ERα signaling pathway. Int J Oncol. 2015; 46(4):1461-72. PMC: 4356499. DOI: 10.3892/ijo.2015.2878. View

14.

Storci G, Sansone P, Trere D, Tavolari S, Taffurelli M, Ceccarelli C . The basal-like breast carcinoma phenotype is regulated by SLUG gene expression. J Pathol. 2007; 214(1):25-37. DOI: 10.1002/path.2254. View

15.

Lane D . Cancer. p53, guardian of the genome. Nature. 1992; 358(6381):15-6. DOI: 10.1038/358015a0. View

16.

Bieging K, Mello S, Attardi L . Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer. 2014; 14(5):359-70. PMC: 4049238. DOI: 10.1038/nrc3711. View

17.

Rinon A, Molchadsky A, Nathan E, Yovel G, Rotter V, Sarig R . p53 coordinates cranial neural crest cell growth and epithelial-mesenchymal transition/delamination processes. Development. 2011; 138(9):1827-38. DOI: 10.1242/dev.053645. View

18.

Yang-Hartwich Y, Tedja R, Roberts C, Goodner-Bingham J, Cardenas C, Gurea M . p53-Pirh2 Complex Promotes Twist1 Degradation and Inhibits EMT. Mol Cancer Res. 2018; 17(1):153-164. PMC: 6800184. DOI: 10.1158/1541-7786.MCR-18-0238. View

19.

Ni T, Li X, Lu N, An T, Liu Z, Fu R . Snail1-dependent p53 repression regulates expansion and activity of tumour-initiating cells in breast cancer. Nat Cell Biol. 2016; 18(11):1221-1232. PMC: 6038146. DOI: 10.1038/ncb3425. View

20.

Chang C, Chao C, Xia W, Yang J, Xiong Y, Li C . p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol. 2011; 13(3):317-23. PMC: 3075845. DOI: 10.1038/ncb2173. View

22.

Puisieux A, Brabletz T, Caramel J . Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol. 2014; 16(6):488-94. DOI: 10.1038/ncb2976. View